These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
523 related articles for article (PubMed ID: 25139660)
1. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide. Ma S; Ma CC Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660 [TBL] [Abstract][Full Text] [Related]
2. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Antonopoulos AS; Margaritis M; Shirodaria C; Antoniades C Thromb Haemost; 2012 Nov; 108(5):840-8. PubMed ID: 22872079 [TBL] [Abstract][Full Text] [Related]
3. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328 [TBL] [Abstract][Full Text] [Related]
4. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Antoniades C; Bakogiannis C; Leeson P; Guzik TJ; Zhang MH; Tousoulis D; Antonopoulos AS; Demosthenous M; Marinou K; Hale A; Paschalis A; Psarros C; Triantafyllou C; Bendall J; Casadei B; Stefanadis C; Channon KM Circulation; 2011 Jul; 124(3):335-45. PubMed ID: 21730307 [TBL] [Abstract][Full Text] [Related]
6. Effects of statins on endothelium and signaling mechanisms. Endres M; Laufs U Stroke; 2004 Nov; 35(11 Suppl 1):2708-11. PubMed ID: 15375300 [TBL] [Abstract][Full Text] [Related]
7. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily. Ma S; Ma CC Cytokine Growth Factor Rev; 2011 Jun; 22(3):167-75. PubMed ID: 21700485 [TBL] [Abstract][Full Text] [Related]
8. Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy? Yuyun MF; Ng LL; Ng GA Microvasc Res; 2018 Sep; 119():7-12. PubMed ID: 29596860 [TBL] [Abstract][Full Text] [Related]
14. Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells. Aoki C; Nakano A; Tanaka S; Yanagi K; Ohta S; Jojima T; Kasai K; Takekawa H; Hirata K; Hattori Y Int J Cardiol; 2012 Apr; 156(1):55-61. PubMed ID: 21093076 [TBL] [Abstract][Full Text] [Related]
15. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779 [TBL] [Abstract][Full Text] [Related]
16. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Channon KM Trends Cardiovasc Med; 2004 Nov; 14(8):323-7. PubMed ID: 15596110 [TBL] [Abstract][Full Text] [Related]